WHO "렘데시비르 코로나19 사망률 저감 효과 없어"<br /><br />Remdesivir is known to be one of the most promising drugs used to treat COVID-19 patients.<br />But a new WHO study reportedly claims it doesn't help reduce mortality rates.<br />Kim Dami has the details.<br />The WHO says the antiviral medication remdesivir has no substantial effect on COVID-19 patients' chances of survival.<br />Developed by Gilead Sciences, remdesivir was among the first to be used as a COVID-19 treatment, known to be effective in shortening recovery time.<br />It was one of the drugs recently used during U.S. President Donald Trump's COVID-19 recovery process.<br />The UK-based Financial Times report cites results from the WHO's Solidarity trial, which evaluated the effects of four potential drugs on over 11-thousand hospitalized patients.<br />The drugs studied were remdesivir, hydroxychloroquine, anti-HIV combination drug of lopinavir/ritonavir and interferon.<br />Among them, hydroxychloroquine and lopinavir/ritonavir were already proven ineffective back in June.<br />In fact, based on the study, none of the four treatments substantially affected mortality rates or reduced the need to ventilate patients.<br />Earlier this month, Gilead Sciences said remdesivir shortened recovery time by five days compared to patients on placebo.<br />In South Korea, around 6-hundred COVID-19 patients at 62 hospitals have been treated with remdesivir.<br />The WHO is yet to comment on the Financial Times' report, saying the study's results have not yet been made public.<br />Kim Dami, Arirang News.<br /><br />
